Alvogen’s subsidiary in Taiwan, Lotus Pharmaceuticals has announced its plans to make significant investment in the development and manufacturing of oncology pharmaceuticals at its facility in Nantou, Taiwan. The investment program is designed to further enhance customer service and supply of high-quality pharmaceuticals for Lotus’ markets around the world.
Lotus’ Nantou site has been audited by Taiwanese, U.S., EU and Japanese regulatory authorities, enabling the facility to manufacture products for nearly every market in the world. In addition to standard solid oral dose manufacturing, Lotus has very unique capabilities around the production of hormonal products, soft gelatin capsules, cytotoxic and high potency molecules.
The Lotus management team graciously acknowledged government officials from TFDA, Nantou County Government, Central Taiwan Science Park, and NanGang Industrial Park for their invaluable roles in advancing the project.